(4-butoxy-benzyl)-carbamic acid 4-methoxy-phenyl ester | 581071-63-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (4-butoxy-benzyl)-carbamic acid 4-methoxy-phenyl ester
• 英文别名: (4-methoxyphenyl) N-[(4-butoxyphenyl)methyl]carbamate
• CAS: 581071-63-8
• 化学式: C₁₉H₂₃NO₄
• 分子量: 329.396
• InChiKey: LCRIEQJXNHPILH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
  申请人：——

  公开号：US20030195226A1

  公开（公告）日：2003-10-16

  The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.

  本发明涉及新型肟羰基衍生物和包含该衍生物的药物组合物，其抑制脂肪酸酰胺水解酶。这些药物组合物对于治疗可以通过抑制脂肪酸酰胺水解酶而受到影响的疾病是有用的，包括但不限于神经病痛、呕吐、焦虑、改变进食行为、运动障碍、青光眼、脑损伤和心血管疾病。
• (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1472215A2

  公开（公告）日：2004-11-03
• EP1472215A4
  申请人：——

  公开号：EP1472215A4

  公开（公告）日：2007-05-09
• US6949574B2
  申请人：——

  公开号：US6949574B2

  公开（公告）日：2005-09-27
• [EN] (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS<br/>[FR] (OXIME)CARBAMOYL, INHIBITEURS DE L'HYDROLASE DES AMIDES D'ACIDES GRAS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003065989A2

  公开（公告）日：2003-08-14

  The present invention relates to novel oxime carbamoyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.